Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease

NCT03594110 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03594110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03594110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2019
Completion date
July 2, 2024
Enrollment
6,609 (actual)
Sites
240

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease